Prostate cancer: Prognostic and predictive factors

L. Fratino, M. C. Aquilano, V. Canzonieri

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Prostate cancer (PC) is the most common cancer in men, in Europe and the United States, and the third leading cause of death from cancer in European men. Clinical factors have been used to stratify prostate cancer patients and to provide guidance on the risk of cancer progression and on treatment needs. PSA screening has led to a loss in the discriminatory power of these clinical and pathologic features; nonetheless, further research is needed to identify molecular drivers of PC which if integrated with clinical factors could improve prognostication. The research for molecular prognostic factors is particularly challenging in prostate cancer given the enormous intratumoral genomic and biological heterogeneity in most early stage PC. The high incidence of PC in Western countries pleads for the investigation of means to distinguish indolent from potentially lethal prostate cancers and an early identification of patients for whom treatment is indicated.

Original languageEnglish
Title of host publicationPrognostic and Predictive Response Therapy Factors in Cancer Disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prostate Cancers)
PublisherNova Science Publishers, Inc.
Pages125-146
Number of pages22
ISBN (Print)9781634635530, 9781634635455
Publication statusPublished - Jan 1 2015

Fingerprint

Prostatic Neoplasms
Neoplasms
Research
Cause of Death
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fratino, L., Aquilano, M. C., & Canzonieri, V. (2015). Prostate cancer: Prognostic and predictive factors. In Prognostic and Predictive Response Therapy Factors in Cancer Disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prostate Cancers) (pp. 125-146). Nova Science Publishers, Inc..

Prostate cancer : Prognostic and predictive factors. / Fratino, L.; Aquilano, M. C.; Canzonieri, V.

Prognostic and Predictive Response Therapy Factors in Cancer Disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prostate Cancers). Nova Science Publishers, Inc., 2015. p. 125-146.

Research output: Chapter in Book/Report/Conference proceedingChapter

Fratino, L, Aquilano, MC & Canzonieri, V 2015, Prostate cancer: Prognostic and predictive factors. in Prognostic and Predictive Response Therapy Factors in Cancer Disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prostate Cancers). Nova Science Publishers, Inc., pp. 125-146.
Fratino L, Aquilano MC, Canzonieri V. Prostate cancer: Prognostic and predictive factors. In Prognostic and Predictive Response Therapy Factors in Cancer Disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prostate Cancers). Nova Science Publishers, Inc. 2015. p. 125-146
Fratino, L. ; Aquilano, M. C. ; Canzonieri, V. / Prostate cancer : Prognostic and predictive factors. Prognostic and Predictive Response Therapy Factors in Cancer Disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prostate Cancers). Nova Science Publishers, Inc., 2015. pp. 125-146
@inbook{b4f25c681036493a8cafa4942031229f,
title = "Prostate cancer: Prognostic and predictive factors",
abstract = "Prostate cancer (PC) is the most common cancer in men, in Europe and the United States, and the third leading cause of death from cancer in European men. Clinical factors have been used to stratify prostate cancer patients and to provide guidance on the risk of cancer progression and on treatment needs. PSA screening has led to a loss in the discriminatory power of these clinical and pathologic features; nonetheless, further research is needed to identify molecular drivers of PC which if integrated with clinical factors could improve prognostication. The research for molecular prognostic factors is particularly challenging in prostate cancer given the enormous intratumoral genomic and biological heterogeneity in most early stage PC. The high incidence of PC in Western countries pleads for the investigation of means to distinguish indolent from potentially lethal prostate cancers and an early identification of patients for whom treatment is indicated.",
author = "L. Fratino and Aquilano, {M. C.} and V. Canzonieri",
year = "2015",
month = "1",
day = "1",
language = "English",
isbn = "9781634635530",
pages = "125--146",
booktitle = "Prognostic and Predictive Response Therapy Factors in Cancer Disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prostate Cancers)",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Prostate cancer

T2 - Prognostic and predictive factors

AU - Fratino, L.

AU - Aquilano, M. C.

AU - Canzonieri, V.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Prostate cancer (PC) is the most common cancer in men, in Europe and the United States, and the third leading cause of death from cancer in European men. Clinical factors have been used to stratify prostate cancer patients and to provide guidance on the risk of cancer progression and on treatment needs. PSA screening has led to a loss in the discriminatory power of these clinical and pathologic features; nonetheless, further research is needed to identify molecular drivers of PC which if integrated with clinical factors could improve prognostication. The research for molecular prognostic factors is particularly challenging in prostate cancer given the enormous intratumoral genomic and biological heterogeneity in most early stage PC. The high incidence of PC in Western countries pleads for the investigation of means to distinguish indolent from potentially lethal prostate cancers and an early identification of patients for whom treatment is indicated.

AB - Prostate cancer (PC) is the most common cancer in men, in Europe and the United States, and the third leading cause of death from cancer in European men. Clinical factors have been used to stratify prostate cancer patients and to provide guidance on the risk of cancer progression and on treatment needs. PSA screening has led to a loss in the discriminatory power of these clinical and pathologic features; nonetheless, further research is needed to identify molecular drivers of PC which if integrated with clinical factors could improve prognostication. The research for molecular prognostic factors is particularly challenging in prostate cancer given the enormous intratumoral genomic and biological heterogeneity in most early stage PC. The high incidence of PC in Western countries pleads for the investigation of means to distinguish indolent from potentially lethal prostate cancers and an early identification of patients for whom treatment is indicated.

UR - http://www.scopus.com/inward/record.url?scp=84955732801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955732801&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84955732801

SN - 9781634635530

SN - 9781634635455

SP - 125

EP - 146

BT - Prognostic and Predictive Response Therapy Factors in Cancer Disease (Colorectal, Breast, Liver, Lung, Gastric, Renal and Prostate Cancers)

PB - Nova Science Publishers, Inc.

ER -